Investigation Report on China Oxiracetam Market, 2010-2019
According to the National bureau of statistics of China, by the end of 2014, the number of Chinese aged above 60 years old is 212.42 million, occupying 15.5% of the total population; the number of Chinese aged above 65 is 137.55 million, occupying 10.1% of the total population. Senile dementia poses a serious threat to old people. According to statistics, about 10% of people aged above 60 suffer from senile dementia, among which 5% have Alzheimei’s Disease (AD). In China, the number of senile dementia cases is estimated to be over 10 million and the incidence of AD doubles for every 5 years of age. There are about 20% of sick old people aged between 80-85 suffer from senile dementia, which strains their families as well as the society.
Oxiracetam, a derivative of pyrrolidone, was first synthesized by ISF in 1974. It is a nootropic drug whose oral preparation and injection entered the Italian market respectively in 1987 and 1990.
Oxiracetam develops fast after entering China, annual sales rising from less than 20 million in 2005 to 1.235 billion in 2014 and CAGR reaching up to 60% during the period of 2005-2014. Oxiracetam enjoys a vast demand in China. Products from CSPC Ouyi Pharmaceutical Co., Ltd, Hunan Jianlang Pharmaceutical Co., Ltd, Harbin Medisan Pharmaceutical Co., Ltd and Guangdong SENCEE Pharmaceutical Co., Ltd all occupy certain share of the market, among which Guangdong SENCEE has the largest market share of 34.16% with sales revenue reaching up to CNY 422 million in 2014.
As the ageing of population becomes more and more serious in China, senile dementia increasingly becomes a severe social problem. The market size of oxiracetam in China is expected to keep growing in the next few years.
Readers can get at least the following information through this report:
market share of manufacturers of oxiracetam in Chinese market
price of oxiracetam in Chinese market
major manufacturers of oxiracetam in China
share of different dosage forms of oxiracetam in Chinese market
market outlook of oxiracetam in China
The author suggests the following groups of people purchase this report:
manufacturers of nootropic drugs
investors/ research institutions interested in Chinese medicine market
any interest in Chinese medicine market, please contact CRI for customized survey service
Please Note: All reports from China Research and Intelligence are written in Chinese, then translated to English. This process takes approximately 5 business days from the date the order is placed